CoChat

Tumor progression in the LPB-Tag transgenic model of prostate cancer is altered by vitamin D receptor and serum testosterone status

Open access
Mordan-McCombs, Sarah, Brown, Theodore, Wang, Wei-Lin Winnie, Gaupel, Ann-Christin, Welsh, JoEllen, Tenniswood, Martin · 2010 · The Journal of Steroid Biochemistry and Molecular Biology
Cited by 50

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

Previous studies have suggested that 1,25 dihydroxyvitamin D3 (1,25(OH)2D3) induces cell cycle arrest and/or apoptosis in prostate cancer cells in vitro, suggesting that vitamin D may be a useful adjuvant therapy for prostate cancer and a chemopreventive agent. Most epidemiological data however shows a weak link between serum 25(OH)D3 and risk of prostate cancer. To explore dichotomy we have compared tumor progression in the LPB-Tag model of prostate in VDR knock out (VDRKO) and wild type (VDRWT) mice. On the C57BL/6 background LPB-Tag tumors progress significantly more rapidly in the VDRKO mice. VDRKO tumors show significantly higher levels of cell proliferation than VDRWT tumors. In mice supplemented with testosterone to restore the serum levels to the normal range, these difference in tumor progression, and proliferation are abrogated, suggesting that there is considerable cross-talk between the androgen receptor (AR) and the vitamin D axis which is reflected in significant changes in steady state mRNA levels of the AR, PCNA, cdk2 survivin and IGFR1 and 2 genes. These alterations may explain the differences between the in vitro data and the epidemiological studies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jsbmb.2010.03.062

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 17

  1. Zhuang, 1998, Antiproliferative, effects of 1α,25-dihydroxyvitamin D3 in human prostate cancer cell line LNCaP involves reduction of cyclin dependent kinase-2 activity and persistent G1 accumulation, Endocrinology, 139, 1197, 10.1210/endo.139.3.5770 · DOI · Paper page
  2. Peehl, 1994, Antiproliferative effects of 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cells, Cancer Res., 54, 805
  3. Murthy, 2005, Androgen receptor signaling and vitamin D receptor action in prostate cancer cells, Prostate, 64, 362, 10.1002/pros.20251 · DOI
  4. L.P.Freedman, 1999, Transcriptional targets of the vitamin D3 receptor-mediating cell cycle arrest and differentiation, J. Nutr., 129, 581S, 10.1093/jn/129.2.581S · DOI
  5. Yang, 2003, Vitamin D inhibits G1 to S progression in LNCaP prostate cancer cells through p27Kip1 stabilization and cdk2 mislocalization to the cytoplasm, J. Biol. Chem., 278, 46864, 10.1074/jbc.M306340200 · DOI
  6. Blutt, 2000, A calcitriol analogue, EB1089, inhibits the growth of LNCaP tumors in nude mice, Cancer Res., 60, 779
  7. Platz, 2004, Plasma 1,25-dihydroxy-and 25-hydroxyvitamin D and subsequent risk of prostate cancer, Cancer Causes Control, 15, 255
  8. Damber, 2008, Prostate cancer, Lancet, 371, 1710, 10.1016/S0140-6736(08)60729-1 · DOI · Paper page
  9. Lou, 2004, 25-Hydroxyvitamin D3 is an active hormone in human primary prostatic stromal cells, FASEB J., 18, 332, 10.1096/fj.03-0140fje · DOI
  10. Kivineva, 1998, Localization of 1,25-dihydroxyvitamin D3 receptor (VDR) expression in human prostate, J. Steroid Biochem. Mol. Biol., 66, 121, 10.1016/S0960-0760(98)00054-5 · doi:10.1016/s0960-0760(98)00054-5
  11. Kasper, 1998, Development, progression and androgen-dependence of prostate tumors in probasin-large T-antigen transgenic mice: a model for prostate cancer, Lab. Invest., 78, 319
  12. Li, 1997, Targeted ablation of the vitamin D receptor: an animal model of vitamin D-dependent rickets type II with alopecia, Proc. Natl. Acad. Sci. U.S.A., 94, 9831, 10.1073/pnas.94.18.9831 · DOI · Paper page
  13. Mordan-McCombs, 2007, Dietary calcium does not affect prostate tumor progression in LPB-Tag transgenic mice, J. Steroid Biochem. Mol. Biol., 103, 747, 10.1016/j.jsbmb.2006.12.073 · doi:10.1016/j.jsbmb.2006.12.073
  14. Leman, 2003, Vitamin D and androgen regulation of prostatic growth, J. Cell. Biochem., 90, 138, 10.1002/jcb.10605 · doi:10.1002/jcb.10605
  15. Bao, 2004, Androgen signaling is required for the vitamin D-mediated growth inhibition in human prostate cancer cells, Oncogene, 23, 3350, 10.1038/sj.onc.1207461 · doi:10.1038/sj.onc.1207461
  16. Cano, 2007, Stromal–epithelial cell interactions and androgen receptor-coregulator recruitment is altered in the tissue microenvironment of prostate cancer, Cancer Res., 511, 10.1158/0008-5472.CAN-06-1478 · DOI
  17. Hidalgo, 2007, Altered VDR-mediated transcriptional activity in prostate cancer stroma, J. Steroid Biochem. Mol. Biol., 103, 731, 10.1016/j.jsbmb.2006.12.072 · DOI

Cited by

See all 50

Metadata

Authors
Mordan-McCombs, S., Brown, T., Wang, W.-L. W., Gaupel, A.-C., Welsh, J., & Tenniswood, M.
Venue
The Journal of Steroid Biochemistry and Molecular Biology
Publisher
Elsevier BV
Published
2010-07
Volume
121
Issue
1-2
Pages
368-371
ISSN
0960-0760 (ISSN-L)
OpenAlex
W2076659431
Cited by
50
References
1
FWCI
3.94
Type
journal article
Language
en
Open access
green
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Funders
  • U.S. Public Health Service
  • National Cancer Institute (RO1 CA101114-01)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.